PacificHealth Laboratories, Inc. Stocks

$ 0Last Updated 23.03.2026

Issuer Rating

Performance

Favourable

Risk

Considerable

Recommendation

Sell

Market Cap

$ 438307

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

PacificHealth Laboratories, Inc. engages in the development of nutritional products that enhance health and athletic performance in the United States and internationally. It primarily focuses on sports performance, hydration, fueling, and muscle recovery. The company provides ENDUROX R4, a muscle recovery drink; ACCELERADE protein powered sports drink; ACCEL GEL, a energy gel; Body Glove Surge; ENDUROX EXCEL, an exercise supplement; and 2ND SURGE, an ultra energy gel. It also offers ACCELERADE HYDRO for less intense workouts use before, during, and after workouts for hydration, energy, and recovery. The company markets its products to various distribution channels, including sports specialty and natural product retailers and chains, as well as markets their products through its Website. PacificHealth Laboratories, Inc. was founded in 1995 and is based in Matawan, New Jersey.

Company Valuation

Greatly undervalued
7/7

From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. In particular, the stock is 'cheap' on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks